Borui biomedical Co., Ltd. received 3 GMP certificates

On December 18, Borui biopharmaceutical (Suzhou) Co., Ltd announced that its subsidiary Xintai Pharmaceutical (Suzhou) Co., Ltd had recently received three GMP certificates issued by Jiangsu Drug Administration of the people's Republic of China 1、 Main information of GMP certificate: 1 Certificate No.: js20191192 Company Name: Xintai Pharmaceutical (Suzhou) Co., Ltd address: C25, C26 and C28 building, No 218, Xinghu street, Suzhou Industrial Park certification scope: small volume injection (pre filled syringe), freeze-dried powder injection valid until: December 4, 2024 2 Certificate No.: js20191193 Company name: Xintai Pharmaceutical (Suzhou) Co., Ltd address: C25 floor, C26 floor and C28 floor, No 218, Xinghu street, Suzhou Industrial Park certification scope: tablet expiry date: December 4, 2024 3 Certificate No.: js20191194 Company Name: Xintai Pharmaceutical (Suzhou) Co., Ltd Address: C25 floor, C26 floor and C28 floor, no.218 Xinghu street, Suzhou Industrial Park; No.22 Binjiang South Road, Taixing Economic Development Zone certification scope: API (micafen sodium) expiry date: December 4, 2024 II Impact on Listed Companies The GMP certificate (No.: js20191192) obtained this time relates to the production line of small volume injection (pre filling syringe) and freeze-dried powder injection, which indicates that the production line of the above-mentioned preparations meets the requirements of the pharmaceutical production quality management specification of the people's Republic of China, indicating that Xintai pharmaceutical is located at 218 Xinghu street, Suzhou Industrial Park No C25 building, C26 building and C28 building can formally produce and sell fondaparinux injection and esmeralazole sodium for injection The GMP certificate (No.: js20191193) obtained this time relates to tablet production line, which indicates that the production line of the above-mentioned preparation products meets the requirements of the pharmaceutical production quality management specification of the people's Republic of China, indicating that the production base of Xintai pharmaceutical, located in C25, C26 and C28 floors, No 218, Xinghu street, Suzhou Industrial Park, can formally produce and sell entecavir tablets The drug GMP Certificate (No.: JS20191194) obtained this time, involving the company's API product Mikafin net sodium, indicates that the above API product production line meets the requirements of the "drug production quality management standard" of the People's Republic of China Adorable adorable